Applied Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Applied TherapeuticsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -21.2% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 79.4% pro Jahr.

Wichtige Informationen

-21.2%

Wachstumsrate der Gewinne

15.5%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	79.4%
Eigenkapitalrendite	-287.6%
Netto-Marge	40,579.5%
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Keine Aktualisierungen

Recent updates

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24

Applied Therapeutics EPS misses by $0.21

Nov 12

Aufschlüsselung der Einnahmen und Ausgaben

Wie Applied Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGM:APLT Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	0	-194	24	0
31 Dec 23	10	-120	21	0
30 Sep 23	11	-97	22	-21
30 Jun 23	11	-73	24	-19
31 Mar 23	11	-70	25	-15
31 Dec 22	0	-83	27	0
30 Sep 22	0	-95	32	59
30 Jun 22	0	-105	36	64
31 Mar 22	0	-105	41	63
31 Dec 21	0	-106	43	63
30 Sep 21	0	-102	42	61
30 Jun 21	0	-104	41	63
31 Mar 21	0	-106	37	69
31 Dec 20	0	-94	33	62
30 Sep 20	0	-88	27	62
30 Jun 20	0	-69	21	49
31 Mar 20	0	-49	17	33
31 Dec 19	0	-46	13	32
30 Sep 19	0	-35	10	24
30 Jun 19	0	-28	7	19
31 Mar 19	0	-23	3	17
31 Dec 18	0	-17	2	11

Qualität der Erträge: APLT ist derzeit unrentabel.

Wachsende Gewinnspanne: APLT ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: APLT ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 21.2% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von APLT verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: APLT ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: APLT hat eine negative Eigenkapitalrendite (-287.64%), da es derzeit unrentabel ist.

Applied Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold US$1.7m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Consensus EPS estimates fall by 36%

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

New major risk - Shareholder dilution

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

New major risk - Financial position

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$13.63

Price target decreased to US$28.80

Applied Therapeutics, Inc. Announces Executive Changes

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Price target increased to US$39.20

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Applied Therapeutics, Inc Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Price target decreased to US$34.40

Price target increased to US$49.40

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Chair of the Board of Directors recently bought US$145k worth of stock

Chief Medical Officer notifies of intention to sell stock

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Chief Medical Officer exercised options and sold US$714k worth of stock

Chief Medical Officer exercised options and sold US$97k worth of stock

Price target decreased to US$44.50

Applied Therapeutics Grants Fast Track Designation by FDA for AT-007 for Galactosemia

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

CFO & Head of Business Development recently sold US$108k worth of stock

Chief Commercial Officer recently sold US$53k worth of stock

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Independent Director exercised options to buy US$1.6m worth of stock.

New 90-day low: US$18.92

Chief Medical Officer exercised options and sold US$86k worth of stock

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Independent Director recently bought US$149k worth of stock

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $69 million.

Chief Medical Officer notifies of intention to sell stock

Applied Therapeutics, Inc. Announces Restart of Pediatric Galactosemia Study

Applied Therapeutics to resume galactosemia study for AT-007

New 90-day high: US$25.41